Michelle Dawson posts

Post published on Twitter/X on 10 Jul 2020 03:28

Back to posts Previous post Next post
Twitter/X Clinical trial clinicaltrials.gov Extract quoted in the post Question asked by Dawson in the post External link integrated into the post Autism terms
Open original post

3 integrated replies by Michelle Dawson

10 Jul 2020 03:33

Note: see also https://t.co/f6oZ4GOQx9 and in case anyone's forgotten, balovaptan for autism received the FDA's "Breakthrough Therapy Designation" in 2018 (look it up)

View reply on Twitter/X

17 Jul 2020 01:38

Update: today, Hoffman-La Roche changed the status of this study from "terminated" to "completed" (?) https://t.co/2z1f4NTr3T

View reply on Twitter/X

25 Jul 2020 02:54

Another update: today, Hoffman-La Roche changed the status of this study from "completed" back to "terminated" https://t.co/GNhLHe8Rco

View reply on Twitter/X

Information about the link integrated into the post

Clinical trial

Hoffmann-La Roche (2018). A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension. ClinicalTrials.gov. Hoffmann-La Roche.

More information

Structured cited links

1 cited resource

Clinical trial Fetched Post and integrated reply clinicaltrials.gov

Hoffmann-La Roche (2018). A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension. ClinicalTrials.gov. Hoffmann-La Roche.

Publication date
8 Aug 2018
Identifier
NCT03504917
Authors
Hoffmann-La Roche
Source
ClinicalTrials.gov
Reference type
clinical_trial
Publisher
Hoffmann-La Roche
Metadata source
clinicaltrials.gov

Abstract

This study will evaluate the efficacy, safety, and pharmacokinetics of 10 mg of oral administration balovaptan once a day (QD) compared with matching placebo in adults (18 years and older) with autism spectrum disorder (ASD).

Open source